ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir
IRB 00080405

ED Provider Instruction Sheet

Your patient has been enrolled in a clinical study comparing oral oseltamivir to IV peramivir. Here is what you can expect:

Study Team Contact:

If you need to reach the study team at any time, please call: **443-326-0534**

If you have questions and would like to discuss with the study PIs, please either ask the coordinator to contact us and/or PING Andrea Dugas or Richard Rothman. We are available 24/7 for study support.

Consent

The study coordinator will describe the study and undergo the consent process with the patient and will sign the consent form as the person obtaining the consent. You will be asked to sign the consent form indicating that you have discussed the risks, benefits, and alternatives, answered any questions, and believe the participant is able to make an informed choice to join the study. If you have any questions, please ask the coordinator to provide you with a copy of the consent form, or discuss with the study PIs.

Laboratory Testing

If not already ordered clinically, the study will perform the following tests:

CBC, CMP, Urine/serum pregnancy (when appropriate), Chest X-ray

If a chest X-ray is needed, you will be asked to order it in EPIC as a "Diagnostic 2 view study". These tests will result in the electronic medical record – we ask that you check the results and consider them in your medical decision-making for the patient.

Some patients may be ineligible for the study due to these laboratory values.

If the patient is ineligible, we will inform you that the patient is discontinued from the study. They will not receive antiviral treatment through the study.

If still eligible, the patient will be randomized to an antiviral treatment arm.

Study Medication

Please do not order any influenza drugs for this patient until instructed to do so.

After randomizing the patient, the coordinator will calculate the patient's creatinine clearance and select the correct influenza dose. They will then show you how to order the study medication through Epic so that the patient is not billed for the drug.

If the patient is assigned to the oseltamivir group: The study will give a full 5 day course. You do not need to give any additional prescription.

If the patient is assigned to the peramivir group: The study will give a single dose of peramivir – as is recommended by the FDA. No further antiviral treatment is needed in non-hospitalized patients.

If the patient is hospitalized, please sign out to the inpatient team that this patient is enrolled in a therapeutic study, and we will contact them to give them further information.